Thiogenesis Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Thiogenesis Therapeutics has a total shareholder equity of CA$4.1M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$4.3M and CA$105.9K respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | n/a |
| Cash | CA$4.15m |
| Equity | CA$4.15m |
| Total liabilities | CA$105.92k |
| Total assets | CA$4.25m |
Recent financial health updates
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20
We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
May 01Recent updates
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
May 01Financial Position Analysis
Short Term Liabilities: TTI's short term assets (CA$4.3M) exceed its short term liabilities (CA$105.9K).
Long Term Liabilities: TTI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TTI is debt free.
Reducing Debt: TTI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TTI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.9% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 01:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Thiogenesis Therapeutics, Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bob Pooler | ValuationLAB AG |